Treatment of SSc-MVECs with sKl led to a significant progressive decrease in active caspase-3 up to 48 hours (p < 0.05 for either 24-hour or 48-hour treatment versus the basal condition) (Fig. 4b). The gene discussed is CASP3; the disease is systemic sclerosis.